• 不 限
  • 期刊论文
  • 硕博论文
  • 会议论文
  • 报 纸
  • 英文论文
  2. 您的位置
  3. 首页
  4. 会议论文
  5. Programmed death ligand 1 as an indicator of preexisting adaptive immune responses in human hepatoce

Programmed death ligand 1 as an indicator of preexisting adaptive immune responses in human hepatoce

来源 :第五届广州国际肿瘤学会议暨第一届中国抗癌协会肿瘤靶向治疗专业委员会年会 | 被引量 : 0次 | 上传用户：liliac
【摘 要】
：
Background: It is well known that the aberrant expression of programmed death ligand 1(PD-L1)on tumor cells impairs antitumor immunity.To date,in hepatocellular carcinoma(HCC),the relationship between
【作 者】
：
Qian-Kun Xie Yu-Jie Zhao Tao Pan Ning Lyu Lu-Wen Mu Shao-Long Li Mu-De Shi Zhen-Feng Zhang Peng-Hui Zhou Ming Zhao 
【机 构】
：
Minimally Invasive Interventional Division,Medical Imaging Center,State Key Laboratory of Oncology i
【出 处】
：
第五届广州国际肿瘤学会议暨第一届中国抗癌协会肿瘤靶向治疗专业委员会年会
【发表日期】
：
2016年11期
【关键词】
：
Adaptive immune resistance CD8+ innate immune resistance INFγ prognosis 
下载到本地 , 更方便阅读
下载此文 赞助VIP
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
　　Background: It is well known that the aberrant expression of programmed death ligand 1(PD-L1)on tumor cells impairs antitumor immunity.To date,in hepatocellular carcinoma(HCC),the relationship between PD-L1 expression and host-tumor immunity is not well defined.Methods: The expression levels of PD-L1 and CD8(+)T cell infiltration were analyzed by immunohistochemistry(IHC)in formalin fixed paraffin embedded(FFPE)specimens from 167 HCC patients undergoing resection.
其他文献
Voltage-gated sodium channel Nav1.5 expression in non-metastatic colon cancer:Association with estro
Background: Voltage gated sodium channel Nav1.5 has been reported potentially promoting metastatic development in colon cancer(CC)cells.To date,the clinical and molecular relevance of Nav1.5 expressio
会议
Nav1.5estrogen receptor βprogesterone receptorp53colon cancer
Oncogene mutational profile predicts tumor regression and survival in locally advanced rectal cancer
Background: Tumor response to preoperative chemoradiotherapy(CRT)and postoperative survival outcome have been shown variance among locally advanced rectal cancer(LARC)individuals.Our study aimed to fi
会议
rectal cancerpreoperative chemoradiotherapyoncogene mutationtumor regression
Transarterial Chemoembolization With or Without Microwave Ablation in the Treatment of Intermediate(
Background: Transarterial chemoembolization(TACE)is currently the first-line treatment for patients with intermediate(BCLC stage B)hepatocellular carcinoma(HCC).However,the prognosis of patients with
会议
hepatocellular carcinomatransarterial chemoembolizationmicrowave ablationBCLC
Transarterial Chemoembolization for Hepatocellular Carcinoma as Downstaging Therapy Before Radiofreq
Background: RFA is currently a curative therapy for patients with hepatocellular carcinoma(HCC)within Milan criteria.As a downstaging procedure,transarterial chemoembolization(TACE)is a way to reduce
会议
hepatocellular carcinomatransarterial chemoembolizationradiofrequency ablation
Abdominal carcinoma group Irreversible Electroporation(IRE)for Locally Advanced Pancreatic Adenocarc
Background: Locally advanced pancreatic cancer(LAPC)patients have a very poor prognosis and limited options for disease control.Local ablation technologies based on thermal damage have been used for t
会议
Irreversible ElectroporationIRELocally Advanced Pancreatic Adenocarcinoma
The correlation between mismatch repair status and clinicopathological characteristics in Chinese sp
Purpose: Our study aimed to explore the relationship between mismatch repair(MMR)status and clinicopathological characteristics in Chinese patients with colorectal cancer(CRC).Patients and methods: A
会议
sporadic colorectal cancermismatch repair genesclinicopathological characteris
Meta-Analysis of Kang'ai injection combined with FOLFIRI for the treatment of colorectal cancer
Objective: Results from publications of Kangai injection+FOLFIRI strategy on colorectal cancer are not consistent.We aimed to determine whether the benefits of Kangai injection+FOLFIRI strategy outwei
会议
Kang'ai injectionFOLFIRIcolorectal cancermeta-analysis
A novel risk score(MCCT)to guide decision for treatment of advanced hepatocellular carcinoma with tr
Background: Transarterial chemoembolisation(TACE)is still widely used to treat patients with advanced hepatocellular carcinoma who have no access to sorafenib in Asia.However,the indication of TACE fo
会议
hepatocellular carcinomatransarterial chemoembolization
Application of circulating tumor cells combined with OCT4 expression for predicting short-term outco
Background: Mounting studies have indicated that circulating tumor cells(CTCs)and OCT4 gene could be used to predict oncologic outcome for colorectal cancer(CRC)patients.The current study aims to moni
会议
Circulating tumor cellsColorectal cancerEMTOCT4 gene expression
Selecting an Optimal Staging System for Intermediate-Stage Hepatocellular Carcinoma:Comparison of 9
Background: It remains unknown which staging system is best in predicting the survival of patients with intermediate stage hepatocellular carcinoma(HCC).We aimed to investigate the performance of nine
会议
hepatocellular carcinomaIntermediate-stageStaging system